6-KThe Wire
Alpha Tau Medical Ltd. files 6-K
Filed May 8, 2026 · 2mo ago · Accession 0001213900-26-053589
Plain English
Alpha Tau Medical Ltd. announced the completion of patient enrollment in its U.S. pivotal skin cancer study, a key step towards potential FDA approval of its Alpha DaRT® treatment for recurrent cutaneous squamous cell carcinoma. This update was provided in a press release dated May 8, 2026.
Filing details
- Company
- Alpha Tau Medical Ltd.
- Ticker
- DRTS
- CIK
- 1871321
- Form type
- 6-K
- Filing date
- May 8, 2026
- Report date
- May 8, 2026
- Document
- ea028978301-6k_alphatau.htm
- Size
- 32 KB